# Optimal Timing of Organs-at-Risk-Sparing Adaptive Radiation Therapy for Headand-Neck Cancer under Re-planning Resource Constraints

Fatemeh Nosrat<sup>1,†</sup>, Cem Dede<sup>2,‡</sup>, Lucas B. McCullum<sup>2,3,‡</sup>, Raul Garcia<sup>1,†</sup>, Abdallah S. R. Mohamed<sup>2,4,‡</sup>, Jacob G. Scott<sup>5</sup>, James E. Bates<sup>6</sup>, Brigid A. McDonald<sup>2,‡</sup>, Kareem A. Wahid<sup>2,‡</sup>, Mohamed A. Naser<sup>2,‡</sup>, Renjie He<sup>2,‡</sup>, Aysenur Karagoz<sup>1,†</sup>, Amy C. Moreno<sup>2,‡</sup>, Lisanne V. van Dijk<sup>2,7</sup>, Kristy K. Brock<sup>8</sup>, Jolien Heukelom<sup>9</sup>, Seyedmohammadhossein Hosseinian<sup>10,†</sup>, Mehdi Hemmati<sup>11,†</sup>, Andrew J. Schaefer<sup>1,†</sup>, Clifton D. Fuller<sup>1,2,†,‡</sup>.<sup>1</sup>

<sup>1</sup>Department of Computational Applied Mathematics and Operations Research, Rice University, Houston, TX, USA <sup>2</sup>Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA <sup>3</sup>The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA <sup>4</sup>Department of Radiation Oncology, Baylor College of Medicine, Houston, TX, USA <sup>5</sup>Department of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland, OH, USA <sup>6</sup>Department of Radiation Oncology, Emory University, Atlanta, GA, USA <sup>7</sup>Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands <sup>8</sup>Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA <sup>9</sup>Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, Netherlands <sup>10</sup>Edward P. Fitts Department of Industrial and Systems Engineering, North Carolina State University, Raleigh, NC, USA <sup>11</sup>School of Industrial and Systems Engineering, University of Oklahoma, Norman, OK, USA

Corresponding Authors: Fatemeh Nosrat (fatemeh.nosrat@rice.edu); Andrew J. Schaefer (andrew.schaefer@rice.edu); Clifton D. Fuller (<u>cdfuller@mdanderson.org</u>)

Abstract word count: 244 Manuscript word count: 3531

<sup>&</sup>lt;sup>†</sup>On behalf of the Rice/MD Anderson Center for Operations Research in Cancer (CORC)

<sup>&</sup>lt;sup>t</sup>On behalf of the MD Anderson Head and Neck Cancer Symptom Working Group

### 1 Abstract.

2 Background and Purpose: Prior work on adaptive organ-at-risk (OAR)-sparing radiation

3 therapy has typically reported outcomes based on fixed-number or fixed-interval re-planning,

4 which represent one-size-fits-all approaches and do not account for the variable progression 5 of individual patients' toxicities. The purpose of this study was to determine the 6 personalized optimal timing for re-planning in adaptive OAR-sparing radiation therapy, 7 considering limited re planning recourses for patients with head and near (UNIC)

7 considering limited re-planning resources, for patients with head and neck cancer (HNC).

8 *Materials and Methods*: A novel Markov decision process (MDP) model was developed 9 to determine optimal timing of re-planning based on the patient's expected toxicity, 10 characterized by normal tissue complication probability (NTCP), for four toxicities. The 11 MDP parameters were derived from a dataset comprising 52 HNC patients treated at the 12 University of Texas MD Anderson Cancer Center between 2007 and 2013. Kernel density 13 estimation was used to smooth the sample distributions. Optimal re-planning strategies were 14 obtained when the permissible number of re-plans throughout the treatment was limited

to 1, 2, and 3, respectively.

16 *Results*: The MDP (optimal) solution recommended re-planning when the difference between

17 planned and actual NTCPs ( $\Delta$ NTCP) was greater than or equal to 1%, 2%, 2%, and 4%

at treatment fractions 10, 15, 20, and 25, respectively, exhibiting a temporally increasing pattern. The  $\Delta$ NTCP thresholds remained constant across the number of re-planning

20 allowances (1, 2, and 3).

21 Conclusion: In limited-resource settings that impeded high-frequency adaptations,  $\Delta NTCP$ 

thresholds obtained from an MDP model could derive optimal timing of re-planning to minimize

the likelihood of treatment toxicities.

24

*Keywords*: Personalized adaptive radiation therapy, organs at risk, normal tissue complication
 probability, Markov decision process, optimal strategy

### 27 1 Introduction

28 Advancements in radiation delivery techniques, such as intensity-modulated radiation therapy

29 (IMRT) and volumetric-modulated arc therapy, enable accurate dose delivery to tumor targets

while minimizing radiation exposure of the surrounding organs at risk (OARs) [1]. However,

30 while minimizing radiation exposure of the surrounding organs at risk (OARs) [1]. However, 31 anatomical changes during the treatment, such as weight loss or tumor shrinkage, may cause the

actual delivered dose to OARs to deviate from the planned dose. This can increase the risk of

33 treatment-induced toxicities, particularly in cases where multiple OARs are in close proximity to the

target, as in head and neck cancer (HNC) [2-4]. To address this, adaptive radiation therapy (ART)

35 has been clinically introduced, proposing on-therapy re-planning in response to anatomical changes

in the target and OARs [5–10].

In practice, however, the clinical implementation of ART with daily (or even less-frequent) replanning remains limited, in large part due to the extensive human/personnel/workflow resources

required to frequently perform key tasks such as segmentation and quality assurance as well as

40 limited device accessibility time [11, 12]. Recent artificial intelligence (AI)-based algorithms (such

41 as auto-segmentation or synthetically created CTs) [13, 14] may mitigate some or all of these process

42 level frictions; however, the integration of such AI tools within the ART workflow is still evolving

[15]. With the advent of hybrid MR-Linac devices, real-time adjustment of daily radiation plans,
known as on-line ART, is now a possibility. On-line ART can also be enabled with the availability

known as on-line ART, is now a possibility. On-line ART can also be enabled with the availability
of high-frequency, high-quality cone- beam CT or CT-on-Rails devices [16, 17]. Regardless of ART

implementation imaging inputs (MR or CT), cancer centers in the U.S. typically have implemented

ART at fixed intervals, notably once mid-therapy [18] and often as a 'verification' of re-simulation.
Most of the relevant studies also only report outcomes on fixed-number and/or fixed-interval replanning [19–21] (see Supplementary Table A1 for a comprehensive literature review). Such predetermined schedules for treatment re-planning, however, take a one-size-fits-all approach and do not

account for the uncertain trajectory of individual patients' toxicities [21], nor patient-specific tumor

regression. As a result, determining the optimal timing of re-planning episodes remains a crucial unmet need, particularly for OAR-sparing adaptive approaches (whether for MR-Linac as we have

unmet need, particularly for OAR-sparing adaptive approaches (whether for MR-Linac as we
 implemented in MR-guided clinical trials [19] or for analogous CT-based approaches [20]).

Heukelom et al. [22] investigated the optimal implementation of ART with a single re-planning 55 allowance (in OAR-sparing radiation therapy) using daily on-treatment CT imaging with a CT-on-rails 56 device. Leveraging the same dataset, this paper presents a new analytical approach to derive optimal 57 re-planning strategies based on Markov decision process (MDP) models. Our aim is to identify the 58 optimal timing for re-planning based on changes in normal tissue complication probabilities (NTCP) 59 of four toxicities: xerostomia, dysphagia, parotid gland dysfunction, and feeding tube dependency at 6 60 61 months post-treatment. We further include allowances in HNC treatment plan adaptations (through 62 limiting the number of available re-plans) to enhance personalized treatment and efficacy. MDPs constitute a class of mathematical optimization models that aim to determine optimal decisions/actions 63 in stochastic dynamic systems [23, 24]. MDPs have been successfully employed to find the optimal 64 timing for various medical interventions [25-31]; however, to our knowledge, MDPs have not been 65 applied for triggering adaptive re-planning. We develop a generalized framework for the utilization 66 of MDPs for evidence-based individualized radiation treatment re-planning, scalable across resource-67 68 rich and resource-limited facilities, and applicable to both CT- and MR-based platforms. Thus, rather than a class solution based on population estimates of toxicity reduction potential, we enable 69 personalized adaptive therapy with consideration of a budget. 70

## 71 2 Materials and Methods

72 2.1 Data

46

This study used a prior dataset of CT-on-Rails image-guided radiation therapy (IGRT), detailed by Heukelom et al. [22], which comprised information from patients treated for HNC at the University of Texas MD Anderson Cancer Center between 2007 and 2013; this retrospective secondary analysis was performed under MD Anderson Cancer Center Institutional Review Board approval (MDA RCR03-0800). The treatments involved (chemo-) radiotherapy with daily CT-on-Rails IGRT. Of the 52 patients, 36 were male and 16 were female. Among them, 46 patients were aged 18-65, while the remaining 6 were older than 65. The primary cancer sites were as

80 follows: Larynx (1 patient), Oropharynx (13), Oral cavity (4), Hypopharynx (0), Nasopharynx (15),

- and Sinonasal (12). Treatment modalities included radiotherapy alone (16 patients), induction
- 82 chemotherapy followed by radiotherapy (2), induction chemotherapy followed by concurrent
- 83 chemoradiation (16), concurrent chemoradiation (14), and radiation plus Cetuximab (4). The
- 84 patients' characteristics are summarized in Supplementary Table B1.

### 85 **Table 1.**

86 Observed  $\Delta$ NTCP values based on the difference between planned dose and actual dose,

- 87 along with the number of patients associated with each  $\Delta$ NTCP value. Adapted from
- 88 [22] with permission.
  - (a) Fraction 10  $\Delta NTCP$ 0% 1% 2% 3% 4% 5% 6% 7% 8% 9% 10% 11% 12% Number of Patients 26 7 4 6 2 2 0 1 0 0 1 1 2 (b) Fraction 15 ΔΝΤCΡ 0% 1% 2% 3% 5% 7% 8% 9% 10% 11% 12% 4% 6% Number of Patients 9 2 23 8 2 1 1 2 0 0 2 1 1
- 91

89

90

92

For these 52 HNC patients, Heukelom et al. [22] calculated deviation of the actual dose from the 93 planned dose for nine OARs at fractions 10 and 15 of the treatment. At each fraction, they estimated 94 NTCP for the toxicities related to the OARs (xerostomia, dysphagia, parotid gland dysfunction, and 95 tube feeding dependency at 6 months post-treatment) by projecting the actual dose through the 96 remainder of the treatment period. Subsequently, they compared these findings with the planned 97 NTCPs and determined the difference, i.e.,  $\Delta$ NTCP, for each toxicity. The NTCP models are 98 presented in Supplementary Table E1. The MDP model presented in this paper used the  $\Delta$ NTCP 99 from this dataset [22], which are summarized in Table 1. For each observed  $\Delta$ NTCP value, 100 Heukelom et al. [22] reported the number of patients for whom this  $\Delta$ NTCP was the highest value 101 among the four NTCP models. 102

103

# 104 2.2 Decision Model

In the MDP model, estimates of an individual patient's toxicity outcome, as a function of the delivered radiation dose to OARs, determine the state of the system at each decision epoch during the treatment (e.g., day). Depending on the observed state, the clinician may decide between two possible actions: (1) Re-plan or (2) continue with the current plan. When the action is to continue with the current plan, the system may transition from one toxicity state to another stochastically, governed by transition probabilities. Re-planning changes the probabilistic transition towards more favorable outcomes/states. Given that a limited number of 're-planning' actions may be taken

- throughout the treatment, an optimal solution to the MDP identifies the optimal timing for taking
- such actions, as a function of the toxicity states. The MDP model captures the stochastic evolution
- of post-treatment toxicity risk and identifies optimal re-planning times to mitigate the toxicities
- 115 (if necessary). The model components are as follows:
- 116 **Re-planning allowance:** Depending on available resources for plan adaptations, the model 117 considered a maximum number of re-plans *B* that could be implemented throughout the treatment. The 118 analysis was performed for B = 1, 2, 3.
- **Decision epochs:** Given a treatment period consisting of 33-35 fractions, the decision epochs were set at fractions 10, 15, 20, and 25. Prior studies have shown that anatomical changes are unlikely to happen very early during the treatment [22]; thus fraction 5 was omitted. Fraction 30 was also excluded due to its proximity to the end of treatment, with negligible impact on the total dose to the OARs.
- 124 States: At each decision epoch, the state of the system was captured by the pair ( $\Delta$ NTCP, b),
- where  $\Delta$ NTCP denoted the deviation of treatment toxicity from the planned value at that time, and
- 126  $b \le B$  was the number of remaining re-plans. For example, if the maximum permissible number
- of re-plans was 2 (B = 2), and the clinician opted to implement a re-plan at fraction 10, then the
- state of the system at fraction 15 became b = 1. The  $\Delta$ NTCP ranged from 0% to 12% in the model
- 129 (Table 1); in computing the number of cases for each reported  $\Delta$ NTCP value, only those patients
- were included who experienced the change of  $\triangle$ NTCP in at least one of the four aforementioned toxicities.
- Actions: At each decision epoch, two possible actions were included: (1) Re-planning, or (2) continuing with the current plan (no re-planning). The stochastic transition of the toxicity state from one decision epoch to the next was a function of the action taken and was determined by the associated transition probabilities. Fig. 1 illustrates the states of the MDP and possible transitions associated with each action at Fractions 10, 15, and 20 along with their smoothed transition probabilities, for the case that at most 2 re-plannings may be performed.
- Transition Probabilities: The transition probabilities, governing the stochastic evolution of toxicity 138 under each action, were estimated using the information presented in Table 1. Under the 'no re-139 planning' action, the probabilities for transitions from fraction 0 to 10 and from fraction 10 to 15 140 were directly estimated based on the number of patients in each  $\Delta$ NTCP category. For example, the 141 probability of transitioning from  $\Delta NTCP = 0\%$  at fraction 0 to  $\Delta NTCP = 1\%$  at fraction 10 is 7/52 142 = 0.13, as 7 patients out of 52 exhibited such a change in  $\Delta$ NTCP from fraction 0 to fraction 10. To 143 make our transition probabilities more realistic with a broader spread and to avoid any deterministic 144 transitions between states, we smoothed out the transition probability matrix from Fraction 10 to 145 15 by using kernel density estimation with Gaussian kernels, implemented in Python [27]. We 146 manually varied the bandwidth between 0 and 1 to observe its effect on the distribution. Based on 147 these tests, we selected a final bandwidth of 0.4, balancing smoothness and fit to capture 148 149 meaningful data patterns without introducing noise. The original and smoothed probabilities associated with the 'no re-planning' action are presented in Supplementary Material C. It was 150

assumed that transition probabilities from fraction 10 to 15 remained constant for subsequent 151 decision epochs, due to the absence of reported  $\Delta$ NTCP information beyond fraction 15 by Heukelom 152 et al. [22]. To model the impact of the 're-planning' action on transition probabilities, it was assumed 153 that, at each decision epoch, the action immediately decreased  $\Delta$ NTCP to a value proportional to the 154 elapsed treatment time. For example, if the 're-planning' action was taken at fraction 10 for 155  $\Delta NTCP = 5\%$ , the state of toxicity would immediately decreased to  $\Delta NTCP = 2\%$  at this fraction, 156 as approximately one third of the treatment period had passed and the dose escalation would not 157 continue through the rest of the treatment; see Fig. 2. Subsequently, the transition from fraction 10 to 158 15 was governed by the probabilities for  $\Delta NTCP = 2\%$ , calculated from Table 1. The probabilities 159 associated with the 're-planning' action, as described above, are presented in Supplementary Material 160 C. 161

**Rewards:** For each set of consecutive actions taken at the decision epoch, the model considered the expected  $-\Delta$ NTCP at the end of the treatment period (with respect to the transition probabilities) as the corresponding reward. The objective of the MDP was to maximize the expected reward by identifying an optimal set of actions, one at each decision epoch, as a function of the system's state. This is referred to as an optimal policy. Because the rewards were defined by negative values in the MDP model, smaller end-treatment  $\Delta$ NTCP values translated to higher rewards.

The optimal policy of an MDP may become a single-threshold policy (also referred to as 169 control-limit policies) [24], which refers to a class of policies that use thresholds on the state value 170 to recommend an action. For this study, a single-threshold policy recommended re-planning when 171 the ANTCP exceeded a threshold, while no re-planning was needed when it falls below the 172 threshold. This implies that if the action for  $\triangle NTCP = x\%$  at a certain decision epoch was to re-173 plan, then for every other state with  $\Delta NTCP = v\% > x\%$  and the same allowance b, the action was 174 also to re-plan. A single-threshold policy reduces the complexity of decision-making to a simple 175 rule that uses only one threshold at each fraction to trigger action and is efficient to implement. 176

177 The MDP was solved using the MDPtoolbox of MATLAB [32], for B = 1, 2, 3. The 178 MATLAB code and its outputs are available at https://figshare.com/s/ 64bc3481737d17fc287e.

179

### 180 **3 Results**

After solving the MDP, the optimal policy, which specified the optimal action ('re-planning' or 'no 181 re-planning') for each state ( $\Delta$ NTCP, b) at each decision epoch, was reported. The analysis revealed 182 183 that the optimal policy was a single-threshold policy, where a specific  $\Delta$ NTCP threshold was assigned to each fraction. When only one re-plan was allowed (B = 1), the optimal policy at fraction 10 was 184 to re-plan for any  $\Delta$ NTCP value greater than or equal to 1%. Subsequently, at fraction 15, this 185 threshold increased to 2% and remained at 2% for fraction 20. At fraction 25, the minimum ANTCP 186 required for a re-planning was 4%. These thresholds remained the same in the optimal policies for B 187 = 2, 3. We summarized the results in Table 2 and provided an illustration in Supplementary Fig. 188

189 D1 for B = 3.

#### 190 **Table 2.**

191	Optimal	re-planning	thresholds	based	on $\triangle NTCP$	and re-pl	lanning all	owance.
-----	---------	-------------	------------	-------	---------------------	-----------	-------------	---------

Re-planning allowance (B)	1	2			3	
Number of remaining re-plans (b)	1	2	1	3	2	1
$\Delta$ NTCP threshold at fraction 10	1%	1%	-	1%	-	-
$\Delta$ NTCP threshold at fraction 15	2%	2%	2%	2%	2%	-
$\Delta$ NTCP threshold at fraction 20	2%	2%	2%	2%	2%	2%
$\Delta$ NTCP threshold at fraction 25	4%	4%	4%	4%	4%	4%

<sup>192</sup> 

#### 193 **4** Discussion

This study introduced the first — to our knowledge — application of the mathematically rigorous MDP methodology, to determine optimal timing of ART in HNC. The MDP model guides clinicians in determining the minimum values of  $\Delta$ NTCP at fractions 10, 15, 20, and 25 for performing a re-plan, given a re-planning allowance of 1, 2, or 3 throughout the treatment.

The re-planning  $\Delta NTCP$  threshold increased over time in the optimal policy, consistent with the 198 diminishing impact of re-planning as the treatment progresses. These values were 1% at fraction 199 10, 2% at fractions 15 and 20, and 4% at fraction 25. Additionally, the results suggest optimality of 200 re-planning for any changes in NTCP ( $\Delta$ NTCP  $\geq$  1) at fraction 10. This supports the findings of 201 Heukelom et al. [22], who identified fraction 10 as the optimal time for a single re-plan. Importantly, 202 at a given fraction, the  $\triangle$ NTCP thresholds remained the same for different number of re-plans (B = 1, 203 2, 3); the re-planning allowance did not affect these thresholds. Furthermore, in cases where  $\Delta$ NTCP 204 at fraction 25 was below the 4% threshold, both options ('re-planning' or 'no re-planning') yielded 205 the same impact on the end-treatment  $\Delta$ NTCP, indicating that re-planning did not result in an 206 improvement. 207

We acknowledge that minimizing the expected  $\Delta$ NTCP may result in prescribing re-planning 208 for any  $\Delta$ NTCP value, potentially leading to a high number of false negatives. This arises from 209 our modeling assumptions, which permitted a fixed number of re-plans at no cost, encouraging 210 frequent re-planning due to low  $\triangle$ NTCP thresholds. In an ongoing study, we are incorporating re-211 planning costs without limiting the number of re-plans to better explore the trade-off between cost 212 and benefit; however, at a minimum, we have opted to err on the side of patient benefit, rather than cost-213 control; as patient NTCP benefit is potentially scalable across any health system, while cost per re-plan 214 and acceptable cost constraints are variable across national and international health policy and 215 reimbursement systems. 216

The significance of a  $\Delta$ NTCP of 4% or below lies in its potential impact on patient outcomes. While seemingly minor, even slight decreases in NTCP can have considerable implications for patient health and well-being. For instance, a reduction in severe toxicity such as osteoradionecrosis by just 4% could significantly enhance the quality of life and long-term survival prospects for patients. Moreover, customizing treatment to achieve such reductions underscores the importance of

personalized care tailored to individual patient needs. By focusing on optimizing treatment outcomes
 at this level, healthcare practitioners can prioritize patient-centric approaches that aim to minimize
 treatment-related toxicity and maximize overall patient benefit.

225

We leveraged an existing CT-on-rails reference dataset [22] to objectively derive the ANTCP 226 listed in the proposed MDP model. It is crucial to acknowledge the limitations regarding the 227 228 generalizability of findings from this single-site retrospective in silico dataset. For instance, the in silico daily dose accumulation was not actively applied to individual patients, but rather calculated 229 post hoc from a high-granularity CT-on-rails daily volumetric IGRT series. The CT-on-rails platform 230 at MD Anderson utilized an in-house custom- constructed intermediary localization and 231 alienation software (CT-Assisted Targeting (CAT)) [33]. Consequently, there were instances where 232 delivered geometric shifts were either unrecorded or unrecoverable, or clearly aberrant (such as extensive 233 shift records representing an initial setup that was then revised after repositioning) during the 234 secondary export of coordinate displacement to the commercial Record and Verify software 235 (Mosaiq, Elekta AB). These discrepancies were subsequently omitted in the in-silico model to 236 streamline data, leading to conceptual gaps in the resultant NTCP modeling where these missing 237 values were not accounted for. Furthermore, it is important to note that this modeled secondary 238 dataset did not include adaptation or daily re-optimization of the initial daily dose in vivo. 239 Consequently, the data presented in this paper should be viewed as a clinically approximate semi-240 synthetic illustrative use-case, rather than a definitive rationale for the large-scale implementation of 241 242 the observed idealized re-planning thresholds across distinct operational platforms. Nonetheless, we believe that the resultant MDP model could be readily scaled using higher-quality prospective or 243 observational cohort data for secondary validation. In essence, the data presented in this paper 244 245 should be regarded as informative rather than definitive, and the individualized planning parameters suggested by MDP should be viewed as proof of concept rather than a formal criterion barring 246 external validation. 247

In the prior work, Heukelom et al. [22] exclusively reported  $\Delta$ NTCP for fractions 10 and 15, 248 consistent with internal re-planning practices at MD Anderson Cancer Center based on data from a 249 Phase II study by Maki et al. [34]. Consequently, for model extensibility in the current application, 250 we have explicitly assumed transition probabilities remain stable for the subsequent epochs. This 251assumption introduced a known level of uncertainty that warrants consideration and is an area of 252 future research, as it has been unclear for specific OARs whether these transition states were indeed 253 stable over therapy. Moreover, the MDP model stipulated weekly re-planning intervals on indexed 254 fractions (e.g., fractions 10, 15, 20, 25, and 30) as a simplification for clarity of presentation reflective 255 256 of our current adaptive protocols [19], but could readily be adapted to continuous daily fraction-based re-planning intervals. 257

The four NTCP models in Supplementary Table E1 are among the most currently used models to calculate the NTCP values for the considered toxicities: xerostomia, dysphagia, parotid gland dysfunction, and feeding tube dependency at 6 months post-treatment [22, 35]. With the advent of more recent NTCP models for HNC radiation therapy, e.g., [36], it is possible that new NTCP models

could offer improved estimations. In addition, the presented results are based on data collected from 52 HNC patients. While we recognize the importance of sample size in calibrating MDPs, this sample size is considered substantial in HNC research, considering that HNC accounts for only about 4% of cancer cases in the United States [37]. Furthermore, our results are contingent upon the available CT-on-Rails data, and future research may benefit from incorporating higherdimensional data (e.g., GTV/the clinical target volume (CTV) modifying approaches, MRI anatomic and/or biomarker data for TCP/NTCP) for a more extensive insight.

Nonetheless, the proposed MDP model for ART is clinically relevant, mathematically rigorous, 269 270 resource-aware, and scalable, and can be adjusted based on new OAR toxicity with reference NTCP values. Necessarily, the precision of the model relies on accurate calculations of NTCP, 271 particularly when adhering to rigorous criteria that determine whether patients are suitable for or 272 excluded from ART [38]. Despite the challenges and limitations, our study introduces novel 273 contributions to the field of ART. Unlike previous works [22], which primarily considered a single 274 re-planning allowance, our optimization model extends its applicability to scenarios with multiple 275re-plans. Furthermore, our optimal policy spans across fractions 10, 15, 20, and 25, representing 276 an advancement beyond the limited scope of Heukelom et al. [22], which only reported results for 277 278 fractions 10 and 15. Gan et al. [39] achieved optimal timing for re-planning in HNC radiation 279 therapy by analyzing weekly dose data through semi-auto segmentation and the K-nearest-280 neighbor method. They constructed a dose deviation map to visualize differences between planned 281 and actual doses, simulating different ART scenarios. By evaluating accumulated dose differences 282 before and after re-planning, the optimal timing for re-planning was determined. Our methodology differs in that we incorporate  $\Delta$ NTCP and utilize it to develop an MDP model for determining the 283 optimal timing for re-planning. 284

285 An aspect not explored in this study is the adaptation based on GTV or CTV modification, either 286 for shrinking GTV/CTVs [19] or isotoxic boost approaches [40, 41]; we concentrated solely on OAR-based adaptation. Adapting based on GTV could open avenues for optimal re-plans, 287 potentially influencing NTCP and extending into scenarios such as Stereotactic Body RT [42]. This 288 289 introduces a distinctive problem and solution space beyond the scope of our current investigation. Furthermore, we exclusively focused on optimizing the ART workflow within the context of photon 290 therapy. Similar optimization methodologies could prove advantageous when exploring ART in the 291 context of proton therapy, particularly in addressing setup variability reduction [43]. For this study, 292 NTCP calculations were based on the 'plan of the day.' While our findings may vary with deformable 293 dose registration, the operational implementation remains consistent. Future efforts should consider 294 incorporating deformable dose registration to enhance the model's generalization. 295

Several surveys in both low/middle-income countries [44, 45] and high-income economies [45] have identified resource constraints as an impediment to ART implementation; the use of models such as our MDP provides a potential avenue for stratification of resource allocation. Put simply, with one re-plan allowed, almost all patients would be best served via re-planning early during treatment; however, as the budget of re-planning staff/technical/time resources expand, evidencebased personalized re-planning is potentiated by our MDP approach.

**Data availability statement:** The anonymized data from the enclosed manuscript has been deposited at DOI:10.6084/m9.figshare.25517338; a referee version is available for review at https://figshare.com/s/64bc3481737d17fc287e.

Preprint availability: A preprint/pre-peer review version of the enclosed manuscript has been
 submitted in accordance with NIH NOT-OD-17-050, "Reporting Preprints and Other Interim
 Research Products" simultaneous with initial submission for peer-review and is available at
 https://doi.org/10.1101/2024.04.01.24305163.

## 309 Acknowledgment

This work was supported by the National Institutes of Health (NIH) National Cancer Institute 310 (NCI) Research Grant (R01CA257814), the NCI Cancer Center Support Grant Program in Image-311 Driven Biologically-informed Therapy (IDBT) Program (P30CA016672), and the Image Guided 312 Cancer Therapy Research Program at The University of Texas MD Anderson Cancer Center, and 313 the MD Anderson Charles and Daneen Stiefel Center for Head and Neck Cancer Oropharyngeal 314 Cancer Research Program. Lucas B. McCullum and Raul Garcia were supported by the NCI 315 Supplement program under R01CA257814-02S2, and R01CA257814-03S2, respectively. Drs. 316 McDonald and Wahid are both supported by the Image-guided Cancer Therapy T32 Fellowship 317 (T32CA261856). Dr. Heukelom received related support from the Netherlands Rene Vogels Fond 318 Fellowship. Drs. Heukelom and van Dijk received relevant support from the Dutch Cancer 319 Society/KWF Kankerbestrijding. Dr. Fuller received related support from the National Institute 320 of Dental and Craniofacial Research (NIDCR) (R01DE028290). Dr. Fuller has received related 321 direct industry grant/in-kind support, honoraria, and travel funding from Elekta AB. Dr. Fuller 322 has served in an unrelated consulting capacity for Varian/Siemens Healthineers. Philips Medical 323 Systems, and Oncospace, Inc. Dr. Brock received unrelated support from the Helen Black Image 324 Guided Fund, RaySearch Laboratories AB, the Apache Corporation, and the Tumor Measurement 325 326 Initiative through the MD Anderson Strategic Initiative Development Program (STRIDE) and various NIH mechanisms. Dr. Scott received relevant support under the NCI Case Comprehensive 327 Cancer Center Support Grant (P30CA043703), with additional unrelated NIH support. Dr. 328 329 Moreno received related support from NIDCR (K01DE030524) and NCI (K12CA088084) during the project period, with additional unrelated NIH support. 330

#### References

- [1] Iacovelli NA, et al. Role of IMRT/VMAT-based dose and volume parameters in predicting 5-year local control and survival in nasopharyngeal cancer patients. Frontiers in Oncology 2020;10:e518110.
- [2] Barker Jr JL, et al. Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. International Journal of Radiation Oncology, Biology, Physics 2004;59(4):960–70.
- [3] Beltran M, Ramos M, Rovira JJ, Perez-Hoyos S, Sancho M, Puertas E, Benavente S, Ginjaume M, Giralt J. Dose variations in tumor volumes and organs at risk during IMRT for head-and-neck cancer. Journal of Applied Clinical Medical Physics 2012;13(6):e3723.
- [4] Chen W, Bai P, Pan J, Xu Y, Chen K. Changes in tumor volumes and spatial locations relative to normal tissues during cervical cancer radiotherapy assessed by cone beam computed tomography. Technology in Cancer Research and Treatment 2017;16(2):246–52.
- [5] Beadle BM, Chan AW. The potential of adaptive radiotherapy for patients with head and neck cancer-too much or not enough? JAMA Oncology 2023; 9(8):1064–65.
- [6] Castelli J, Simon A, Lafond C, Perichon N, Rigaud B, Chajon E, De Bari B, Ozsahin M, Bourhis J, de Crevoisier R. Adaptive radiotherapy for head and neck cancer. Acta Oncology 2018;57(10):1284–92.
- [7] Figen M, Öksüz DÇ, Duman E, Prestwich R, Dyker K, Cardale K, Ramasamy S, Murray P, Şen M. Radiotherapy for head and neck cancer: Evaluation of triggered adaptive replanning in routine practice. Frontiers in Oncology 2020;59(4):960-70.
- [8] Håkansson K, Giannoulis E, Lindegaard A, Friborg J, Vogelius I. CBCT-based online adaptive radiotherapy for head and neck cancer-dosimetric evaluation of first clinical. Acta Oncologica 2023; 62(11):1369–1374.
- [9] Lavrova E, Garrett MD, Wang YF, Chin C, Elliston C, Savacool M, Price M, Kachnic LA, Horowitz DP. Adaptive radiation therapy: A review of CT-based techniques. Radiology. Imaging Cancer 2023; 5(4):e230011.
- [10] O'Hara CJ, Bird D, Al-Qaisieh B, Speight R. Assessment of CBCT-based synthetic CT generation accuracy for adaptive radiotherapy planning. Journal of Applied Clinical Medical Physics 2022; 23(11):e13737.
- [11] Brock KK. Adaptive radiotherapy: Moving into the future. Seminars in Radiation Oncology 2019; 29(3):181–184.
- [12]Wahid, KA et al. Harnessing uncertainty in radiotherapy auto-segmentation quality assurance. Physics and Imaging in Radiation Oncology 2023; 29:100526.
- [13]Allen C, Yeo AU, Hardcastle N, Franich RD. Evaluating synthetic computed tomography images for adaptive radiotherapy decision making in head and neck cancer. Physics and Imaging in Radiation Oncology 2023; 27:100478.
- [14]Taasti VT, et al. Clinical evaluation of synthetic computed tomography methods in adaptive

proton therapy of lung cancer patients. Physics and Imaging in Radiation Oncology 2023;27:e100459.

- [15] Huynh E, Hosny A, Guthier C, Bitterman SF, Hass-Kogan DA, Kann B, Aerts HJWL, Mak RG. Artificial intelligence in radiation oncology. Nature Reviews Clinical Oncology 2020; 17:771–81.
- [16] van de Schoot AJ, Hoffmans D, van Ingen KM, Simons MJ, Wiersma J. Characterization of Ethos therapy systems for adaptive radiation therapy: A multi- machine comparison. Journal of Applied Clinical Medical Physics 2023;24:e13905.
- [17] Varian Ethos. <u>https://www.varian.com</u>; 2024 [accessed 24 February 2024].
- [18] Avgousti R, Antypas C, Armpilia C, Simopoulou F, Liakouli Z, Karaiskos P, Kouloulias V, Kyrodimos E, Moulopoulos LA, Zygogianni A. Adaptive radiation therapy: When, how and what are the benefits that literature provides? Cancer Radiotherapie: Journal de la Societe Francaise de Radiotherapie Oncologique 2022;26(4):622–36.
- [19] Bahig H, et al. Magnetic resonance-based response assessment and dose adaptation in human papilloma virus positive tumors of the oropharynx treated with radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clinical and Translational Radiation Oncology 2018;13:19–23.
- [20] Castelli J, et al. Weekly adaptive radiotherapy vs standard intensity-modulated radiotherapy for improving salivary function in patients with head and neck cancer: A phase 3 randomized clinical trial. JAMA Oncology 2023;9(8):1056–64.
- [21] Westerhoff JM, et al. Safety and tolerability of online adaptive high-field magnetic resonanceguided radiotherapy. JAMA Network Open 2024;7(5):e2410819.
- [22] Heukelom J, et al. Differences between planned and delivered dose for head and neck cancer, and their consequences for normal tissue complication probability and treatment adaptation. Radiotherapy and Oncology 2020;142:100–6.
- [23] Feinberg EA, Shwartz A. Handbook of Markov Decision Processes: Methods and Applications. New York: Springer; 2002.
- [24] Puterman ML. Markov Decision Processes: Discrete Stochastic Dynamic Programming. New York: Wiley-Interscience; 2005.
- [25] Beck JR, Pauker SG. The Markov process in medical prognosis. Medical Decision Making 1983;3(4):419–58.
- [26] Kuntz KM, Russell LB, Owens DK, Sanders GD, Trikalinos TA, Salomon JA. Decision models in cost-effectiveness analysis. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 2016.
- [27] Ng SP et al. Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. Cancer 2020;126(4):749–56.
- [28] Alagoz O, Hsu H, Schaefer AJ, Roberts MS. Markov decision processes: A tool for sequential decision making under uncertainty. Medical Decision Making: An International Journal of the Society for Medical Decision Making 2010;30(4):474–83.
- [29] Alagoz O, Maillart LM, Schaefer AJ, Roberts MS. The optimal timing of living-donor liver transplantation. Management Science 2004;50(10):1420–30.

- [30] Denton BT, Kurt M, Shah ND, Bryant SC, Smith SA. Optimizing the start time of statin therapy for patients with diabetes. Medical Decision Making 2009;29(3):351–67.
- [31] Shechter SM, Bailey MD, Schaefer AJ, Roberts MS. The optimal time to initiate HIV therapy under ordered health states. Operations Research 2008;56(1):20–33.
- [32] MATLAB version: 9.13.0 (R2022b), Natick, Massachusetts: The MathWorks Inc.; 2022.
- [33] Zhang L, Dong L, Court L, Wang H, Gillin M, Mohan R. TU-EE-A4-05: Validation of CTassisted targeting (CAT) software for soft tissue and bony target localization. Medical Physics 2005;32:2106.
- [34] Maki RG, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2009;27(19):3133–40.
- [35] Stieb S, Lee A, van Dijk LV, Frank S, Fuller CD, Blanchard P. NTCP modeling of late effects for head and neck cancer: A systematic review. International Journal of Particle Therapy 2021;8(1):95–107.
- [36] Hosseinian S, Hemmati M, Dede C, Salzillo TC, van Dijk LV, Mohamed ASR, Lai SY, Schaefer AJ, Fuller CD. Cluster-based toxicity estimation of osteoradionecrosis via unsupervised machine learning: Moving beyond single dose-parameter normal tissue complication probability by using whole dose-volume histograms for cohort risk stratification. International Journal of Radiation Oncology, Biology, Physics 2024;119(5):1569–78.
- [37] American Cancer Society. Head and Neck Cancer: Statistics. https://www.cancer.net/cancer-types/head-and-neck-cancer/statistics; 2024 [accessed 24 February 2024].
- [38] Gan Y, Langendijk JA, van der Schaaf A, van den Bosch L, Oldehinkel E, Lin Z, Both S, Brouwer CL. An efficient strategy to select head and neck cancer patients for adaptive radiotherapy. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 2023;186:e109763.
- [39] Gan Y, Langendijk JA, Oldehinkel E, Lin Z, Both S, Brouwer CL. Optimal timing of re-planning for head and neck adaptive radiotherapy. Journal of the European Society for Therapeutic Radiology and Oncology 2024;194:e110145.
- [40] Heukelom J, et al. Adaptive and innovative radiation treatment for improving cancer treatment outcome (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer 2013;13:84.
- [41] Leeuw AD, et al. Acute toxicity in ARTFORCE: A randomized phase III dose-painting trial in head and neck cancer. International Journal of Radiation Oncology, Biology, Physics 2022;114(3):S98.
- [42] Mohamad I, et al. The evolving role of stereotactic body radiation therapy for head and neck cancer: Where do we stand? Cancers (Basel) 2023;15(20):e5010.
- [43] Lalonde A, Bobić M, Sharp GC, Chamseddine I, Winey B, Paganetti H. Evaluating the effect of setup uncertainty reduction and adaptation to geometric changes on normal tissue complication probability using online adaptive head and neck intensity modulated proton therapy. Physics in

Medicine and Biology 2023;68(11):e115018.

- [44] Yap LM, Jamalludin Z, Ng AH, Ung NM. A multi-center survey on adaptive radiation therapy for head and neck cancer in Malaysia. Physical and Engineering Sciences in Medicine 2023;46(3):1331–40.
- [45] Bertholet J, et al. Patterns of practice for adaptive and real-time radiation therapy (POP-ART RT) part II: Offline and online plan adaption for interfractional changes. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 2020;153:88–96.



**Graphical Abstract:** Overview of the analysis method. The sub-figures displaying Organs at risk and toxicities are adapted from [1] with permission. Abbreviation: NTCP = Normal tissue complications probability.

### References

 Fuller CD. Introduction to Radiation Oncology, https://doi.org/10.6084/m9.figshare .22582207.v1; 2023 [accessed 24 February 2024].



Fig. 1: Markov Decision Process Model. The permissible number of re-plans is 2 (B = 2). The states are shown by ellipses.  $\Delta$ NTCP values are located in the upper half of the ellipses, while the lower halves contain the value of b (the number of remaining re-plans). Transitions between states are shown by green arrows when the action is 'no re-planning' and by red arrows when the action is 're-planning.' Not all arrows, states, and fractions are included to avoid ambiguity. For example, the smoothed transition probability from state (2%,2) state to (1%,1) when the action is 're-planning' is 0.86.



Fig. 2: Effect of actions on system transitions. The permissible number of re-plans is 2 (B = 2). The states are represented by ellipses. The  $\Delta$ NTCP values are located in the upper halves of the ellipses, while the lower halves contain the value of b (the number of remaining re-plans). When the action at a fraction is 're-planning,' as in Fractions 10 and 15 in Part A and Fraction 10 in Part B, the transition to a state with a lower  $\Delta$ NTCP within the same fraction is shown with red arrows. Transitions between states from one fraction to the next are shown with blue arrows. When the action is 'no re-planning,' as in Fraction 15 in Part B, no transition occurs within that fraction. Instead, the system transitions to a new state at Fraction 20. This is depicted by the gray states at Fraction 15, indicating that there is no immediate decrease in  $\Delta$ NTCP.

#### Supplementary Material A. Literature Review on Head-and-neck-cancer Adaptive Radiation Therapy.

Paper	Replan Trigger	Replan Frequency
Castelli et al. [1]	None	Replan weekly
Lim et al. [2]	Parotid dose	Replan at F14
McDonald et al. [3]	Weight loss or	Case studies of replans on four patients,
		one at F6, F8, F24, F26
Reinders et al. [4]	None	Replan weekly
Kee et al. [5]	Tumor ADC	Replan at week 2 and 4, Increase dose at F10
Ciarmatori et al. [6]	None	Single replan at F18
Maffei et al. [7]	None	Optimal replan at F18
Wang et al. [8]	None	Single replan at F18
Gros et al. [9]	Dosimetric factors	Optimal replan between F1 and F23
Duma et al. [10]	Weight loss	Replan varied from F6 to F20
Fung et al. [11]	None	Replan after F25 and F35
Kuo et al. [12]	None	Replan after F25
Hansen et al. [13]	Weight loss or	Replan after F19 $\pm$ 6
	tumor shrinkage	
Capelle et al. [14]	None	Replan at F20
Brwon et al. [15]	Source-to-skin	Median re-planning at F22 and F26
	distance corrections	
Castelli et al. [16]	None	Replan weekly
Brown et al. [17]	Nodal volume	Median re-planning at F11 for nasopharyngeal
		and at F20 for oropharyngeal
Aly et al. [18]	None	Replan weekly
Figen et al. [19]	Weight loss or	Mean replan at F15
	tumor shrinkage	
Bobi'c et al. [20]	None	Replan weekly
Gupta et al. [21]	None	Replan daily

**Table A1:** A comprehensive list of relevant papers on head-and-neck-cancer ART along with the number of re-plan and the reported fractions.

### Supplementary Material B. Patient Characteristics.

Variable	Number of Patients $= 52$	Percentage
Sex	Male	69%
	Female	31%
Age	18-65 years	88%
-	$\geq 65$ years	12%
T-classification	Tis-T1	8%
	T2	15%
	Т3	13%
	T4	54%
	Recurrence	8%
	Unknown	2%
	Post-surgery	23%
N-classification	NO	27%
	N1	19%
	N2	38%
	N3	2%
Primary site	Larynx	2%
-	Oropharynx	25%
	Oral cavity	8%
	Hypopharynx	0%
	Nasopharynx	29%
	Sinonasal	23%
Pathology	Adenocarcinoma	2%
	Neuroblastoma	6%
	Neuroendocrine	8%
	Squamous cell carcinoma	50%
	Undifferentiated carcinoma	17%
	Other	17%
Treatment modality	Radiotherapy alone	31%
	Induction chemotherapy followed by RT	4%
	Induction chemotherapy followed by cCRT	31%
	Concurrent chemoradiation	27%
	Radiation + Cetuximab	8%
Baseline weight loss	No weight loss	38%
	Moderate weight loss $(1 - 10\%)$	33%
	Severe weight loss (>10%)	6%
	Unknown	23%
Baseline xerostomia	No xerostomia	4%
	Some xerostomia	8%
	Unknown	88%
Accelerated RT	Yes	6%

**Table B1:** Patient characteristics. Abbreviations: cCRT = concurrent chemoradiation. RT = radiotherapy. TNMclassification according to version 3. Accelerated RT: 2 Gy per fraction, 6 times per week.

#### Supplementary Material C. Transition Probabilities.

### Action 1: No re-planning

The natural transition probabilities from fraction 0 (pre-treatment) to fraction 10 were directly estimated using the information provided in Table 1. For each  $\Delta$ NTCP category, the ratio of the corresponding number of patients at fraction 10 to the total of 52 patients was taken as the associated transition probability. We note that all patients exhibit

 $\Delta$ NTCP = 0% at fraction 0. These probabilities apply only to the states with the same number of remaining re-plans *b*, by the definition of the 'no re-planning' action. The transition probabilities are presented in Supplementary Table C1.

Table C1: Transition probabilities from fraction 0 (F0) to fraction 10 (F10) under 'no re-planning.'

$\Delta NTCP @ F10 \rightarrow$	0%	1%	2%	3%	4%	5%	6%	7%	8%	9%	10%	11%	12%
$\Delta$ NTCP @ F0 $\downarrow$													
0%	0.50	0.13	0.08	0.11	0.04	0.04	0.00	0.02	0.00	0.00	0.02	0.02	0.04

The natural transition probabilities from fraction 10 to fraction 15 were estimated in a similar manner. As the number of patients in each  $\Delta$ NTCP category at fraction 15 were aggregated, a mapping from  $\Delta$ NTCP categories at fraction 10 to those of fraction 15 was established. To ensure a feasible map, it was assumed that  $\Delta$ NTCPs may slightly improve (1%) on its own, without intervention. The necessity of this assumption may be observed by the number of patients with  $\Delta$ NTCP = 12% at Fraction 10 and 15 in Table 1; two patients exhibited  $\Delta$ NTCP = 12% at fraction 10, while this number at fraction 15 was one patient. As no patient showed  $\Delta$ NTCP = 6%, 8%, 9% at fraction 10, it was assumed that the patients in these categories retain the same  $\Delta$ NTCP at fraction 15 with probability 1. The transition probabilities are presented in Supplementary Table C2.

**Table C2:** Transition probabilities from fraction 10 (F10) to fraction 15 (F15) under 'no re-planning.' The same probabilities apply to subsequent transitions, i.e., from F15 to F20, from F20 to F25, and from F25 to end-treatment, under 'no re-planning.'

$\Delta NTCP @ F15 \rightarrow$	0%	1%	2%	3%	4%	5%	6%	7%	8%	9%	10%	11%	12%
$\Delta$ NTCP $(\tilde{a})$ F10 $\downarrow$													
0%	0.88	0.00	0.12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
1%	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
2%	0.00	0.25	0.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
3%	0.00	0.00	0.50	0.33	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
4%	0.00	0.00	0.00	0.00	0.50	0.00	0.50	0.00	0.00	0.00	0.00	0.00	0.00
5%	0.00	0.00	0.00	0.00	0.00	0.50	0.00	0.50	0.00	0.00	0.00	0.00	0.00
6%	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
7%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
8%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00
9%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00
10%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00
11%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00
12%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.50

**Table C3:** Smoothed Transition probabilities from fraction 10 (F10) to fraction 15 (F15) under 'no re- planning.' The same probabilities apply to subsequent transitions, i.e., from F15 to F20, from F20 to F25, and from F25 to end-treatment, under 'no re-planning.'

$\Delta NTCP @ F15 \rightarrow$	0%	1%	2%	3%	4%	5%	6%	7%	8%	9%	10%	11%	12%
$\Delta$ NTCP @ F10 $\downarrow$													
0%	0.81	0.08	0.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
1%	0.07	0.86	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
2%	0.01	0.28	0.66	0.04	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
3%	0.00	0.03	0.46	0.31	0.17	0.01	0.02	0.00	0.00	0.00	0.00	0.00	0.00
4%	0.00	0.00	0.02	0.03	0.43	0.06	0.42	0.04	0.00	0.00	0.00	0.00	0.00
5%	0.00	0.00	0.00	0.00	0.04	0.43	0.09	0.42	0.02	0.00	0.00	0.00	0.00
6%	0.00	0.00	0.00	0.00	0.00	0.06	0.85	0.09	0.00	0.00	0.00	0.00	0.00
7%	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.85	0.08	0.00	0.00	0.00	0.00
8%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.85	0.08	0.00	0.00	0.00
9%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.85	0.08	0.00	0.00
10%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.08	0.88	0.04	0.00
11%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.88	0.06	0.02
12%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.46	0.48

#### Action 2: Re-planning

The impact of 're-planning' on transition probabilities at a specific fraction was modeled by presuming an immediate reduction in  $\Delta$ NTCP to a proportion relative to the elapsed treatment time, followed by a natural transition governed by the probabilities associated with the reduced  $\Delta$ NTCP. For instance, 're-planning' at fraction 10 when  $\Delta$ NTCP is at 5% results in an immediate decrease to  $\Delta$ NTCP = 2%, reflecting that about one-third of the treatment has been completed. This is then followed by a transition (from F10 to F15) according to the probabilities associated with  $\Delta$ NTCP = 2% @ F10 in Supplementary Table C2. These probabilities are presented in the following tables. We note that the earliest decision epoch for 're-planning' is fraction 10.

Table C4: Transition probabilities from fraction	10 (F10) to fraction	15 (F15) under	're-planning.'
--	----------------------	----------------	----------------

$\Delta NTCP @ F15 \rightarrow$	0%	1%	2%	3%	4%	5%	6%	7%	8%	9%	10%	11%	12%
$\Delta$ NTCP $@$ F10 $\downarrow$													
0%	0.81	0.08	0.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
1%	0.81	0.08	0.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
2%	0.07	0.86	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
3%	0.07	0.86	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
4%	0.07	0.86	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5%	0.01	0.28	0.66	0.04	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
6%	0.01	0.28	0.66	0.04	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
7%	0.01	0.28	0.66	0.04	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
8%	0.00	0.03	0.46	0.31	0.17	0.01	0.02	0.00	0.00	0.00	0.00	0.00	0.00
9%	0.00	0.03	0.46	0.31	0.17	0.01	0.02	0.00	0.00	0.00	0.00	0.00	0.00
10%	0.00	0.03	0.46	0.31	0.17	0.01	0.02	0.00	0.00	0.00	0.00	0.00	0.00
11%	0.00	0.00	0.02	0.03	0.43	0.06	0.42	0.04	0.00	0.00	0.00	0.00	0.00
12%	0.00	0.00	0.02	0.03	0.43	0.06	0.42	0.04	0.00	0.00	0.00	0.00	0.00

$\Delta NTCP @ F20 \rightarrow$	0%	1%	2%	3%	4%	5%	6%	7%	8%	9%	10%	11%	12%
$\Delta$ NTCP @ F15 $\downarrow$													
0%	0.81	0.08	0.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
1%	0.07	0.86	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
2%	0.07	0.86	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
3%	0.01	0.28	0.66	0.04	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
4%	0.01	0.28	0.66	0.04	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5%	0.00	0.03	0.46	0.31	0.17	0.01	0.02	0.00	0.00	0.00	0.00	0.00	0.00
6%	0.00	0.03	0.46	0.31	0.17	0.01	0.02	0.00	0.00	0.00	0.00	0.00	0.00
7%	0.00	0.00	0.02	0.03	0.43	0.06	0.42	0.04	0.00	0.00	0.00	0.00	0.00
8%	0.00	0.00	0.02	0.03	0.43	0.06	0.42	0.04	0.00	0.00	0.00	0.00	0.00
9%	0.00	0.00	0.00	0.00	0.04	0.43	0.09	0.42	0.02	0.00	0.00	0.00	0.00
10%	0.00	0.00	0.00	0.00	0.04	0.43	0.09	0.42	0.02	0.00	0.00	0.00	0.00
11%	0.00	0.00	0.00	0.00	0.00	0.06	0.85	0.09	0.00	0.00	0.00	0.00	0.00
12%	0.00	0.00	0.00	0.00	0.00	0.06	0.85	0.09	0.00	0.00	0.00	0.00	0.00

Table C5: Transition probabilities from fraction 15 (F15) to fraction 20 (F20) under 're-planning.'

Table C6: Transition probabilities from fraction 20 (F20) to fraction 25 (F25) under 're-planning.'

$\Delta NTCP @ F25 \rightarrow$	0%	1%	2%	3%	4%	5%	6%	7%	8%	9%	10%	11%	12%
$\Delta$ NTCP $@$ F20 $\downarrow$													
0%	0.81	0.08	0.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
1%	0.07	0.86	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
2%	0.07	0.86	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
3%	0.01	0.28	0.66	0.04	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
4%	0.00	0.03	0.46	0.31	0.17	0.01	0.02	0.00	0.00	0.00	0.00	0.00	0.00
5%	0.00	0.03	0.46	0.31	0.17	0.01	0.02	0.00	0.00	0.00	0.00	0.00	0.00
6%	0.00	0.00	0.02	0.03	0.43	0.06	0.42	0.04	0.00	0.00	0.00	0.00	0.00
7%	0.00	0.00	0.00	0.00	0.04	0.43	0.09	0.42	0.02	0.00	0.00	0.00	0.00
8%	0.00	0.00	0.00	0.00	0.04	0.43	0.09	0.42	0.02	0.00	0.00	0.00	0.00
9%	0.00	0.00	0.00	0.00	0.00	0.06	0.85	0.09	0.00	0.00	0.00	0.00	0.00
10%	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.85	0.08	0.00	0.00	0.00	0.00
11%	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.85	0.08	0.00	0.00	0.00	0.00
12%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.85	0.08	0.00	0.00	0.00

Table C7: Transition probabilities from fraction 25 (F25) to end-treatment under 're-planning.'

$ANTCP @ end \rightarrow$	0%	1%	2%	3%	4%	5%	6%	7%	8%	9%	10%	11%	12%
$\Delta$ NTCP @ F25 $\downarrow$				• • •		• • •							
0%	0.81	0.08	0.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
1%	0.07	0.86	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
2%	0.01	0.28	0.66	0.04	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
3%	0.00	0.03	0.46	0.31	0.17	0.01	0.02	0.00	0.00	0.00	0.00	0.00	0.00
4%	0.00	0.03	0.46	0.31	0.17	0.01	0.02	0.00	0.00	0.00	0.00	0.00	0.00
5%	0.00	0.00	0.02	0.03	0.43	0.06	0.42	0.04	0.00	0.00	0.00	0.00	0.00
6%	0.00	0.00	0.00	0.00	0.04	0.43	0.09	0.42	0.02	0.00	0.00	0.00	0.00
7%	0.00	0.00	0.00	0.00	0.00	0.06	0.85	0.09	0.00	0.00	0.00	0.00	0.00
8%	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.85	0.08	0.00	0.00	0.00	0.00
9%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.85	0.08	0.00	0.00	0.00
10%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.85	0.08	0.00	0.00	0.00
11%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.85	0.08	0.00	0.00
12%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.08	0.88	0.04	0.00



#### Supplementary Material D. Optimal *ANTCP* Thresholds for Re-planning.

**Fig. D1:** Optimal  $\triangle$ NTCP thresholds for re-planning for B = 3. Optimal  $\triangle$ NTCP thresholds for re-planning at fractions 10, 15, 20, and 25 are 1%, 2%, 2%, and 4%, respectively. The optimal  $\triangle$ NTCP thresholds increase with respect to fraction but remain constant with respect to the number of replans remaining.

#### Supplementary Material E. NTCP Models.

**Table E1:** The employed NTCP models for xerostomia, dysphagia, parotid gland dysfunction, and feeding tube dependency at 6 months post-treatment.

1. NTCP model for moderate to severe xerostomia at 6 months [22].

NTCP =  $(1 + e^{-S})^{-1}$ , where S = -1.443 + (mean dose to contralateral parotid \* 0.047) + (baseline xerostomia score \* 0.720). Baseline xerostomia is 0 (none) or 1 (a bit).

2. NTCP model for physician rated feeding tube dependency at 6 months [23]

NTCP =  $(1 + e^{-S})^{-1}$ , where S = -11.70 + (advanced T-stage \* 0.43) + (moderate weight loss \* 0.95)+ (severe weight loss \* 1.63) + (accelerated radiotherapy \* 1.20) + (chemoradiation \* 1.91) + (radiotherapy plus cetuximab \* 0.56) + (mean dose PCM superior \*0.071) + (mean dose PCM inferior \* 0.034) + (mean dose contralateral parotid \* 0.006) + (mean dose cricopharyngeal muscle \* 0.023). The dose variables are in Gy, and for all the other variables 0 (no) or 1 (yes) are filled in.

3. NTCP model for physician rated decreased salivary flow using the mean dose model [24-26].

NTCP =  $\frac{1}{\sqrt{2\pi}} \int_{-\infty}^{u} e^{\frac{-t^2}{2}} dt$ , where  $u = \frac{D - TD_{50}}{mTD_{50}}$ 

*D* is the mean parotid dose,  $TD_{50}$  is the dose resulting in 50% complication probability and *m* determines the slope of the model. The employed parameters were  $TD_{50}$ =39.9 Gy and m = 0.4.

**4.** NTCP model for dysphagia (grade 2–4 swallowing dysfunction according to the RTOG/EORTC Late Radiation Morbidity Scoring Criteria, physician rated 6 months after treatment) [27].

NTCP =  $(1 + e^{-S})^{-1}$ , where S = -6.09+ (mean dose PCM superior \* 0.057) + (mean dose supraglottic larynx \* 0.037).

### References

- Castelli J, et al. Weekly adaptive radiotherapy vs standard intensity-modulated radiotherapy for improving salivary function in patients with head and neck cancer: A phase 3 randomized clinical trial. JAMA Oncology 2023;9(8):1056–64.
- [2] Lim SY, Tran A, Tran ANK, Sobremonte A, Fuller CD, Simmons L, Yang J. Dose accumulation of daily adaptive plans to decide optimal plan adaptation strategy for head-and-neck patients treated with MR-Linac. Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists 2022;47(1):103–9.
- [3] McDonald BA, et al. Initial feasibility and clinical implementation of daily MR- guided adaptive head and neck cancer radiation therapy on a 1.5T MR-Linac system: Prospective R-IDEAL 2a/2b systematic clinical evaluation of technical innovation. International Journal of Radiation Oncology, Biology, Physics 2021;109(5):1606–18.
- [4] Reinders FCJ, de Ridder M, Doornaert PAH, Raaijmakers CPJ, Philippens MEP. Individual elective lymph node irradiation for the reduction of complications in head and neck cancer patients (iNode): A phase-I feasibility trial protocol. Clinical and Translational Radiation Oncology 2022;39:e100574.
- [5] H. Kee, et al. Optimising radiation therapy in head and neck cancers using functional image-guided radiotherapy and novel biomarkers. <u>https://clinicaltrials.gov/study/NCT04242459</u>; 2021 [accessed 16 September 2024].
- [6] Ciarmatori A, Maffei N, Mistretta GM, Ceroni P, Bernabei A, Meduri B, D'Angelo E, Bruni A, Giacobazzi P, Lohr F, Guidi G. Evaluation of the effectiveness of novel single-intervention adaptive radiotherapy strategies based on daily dose accumulation. Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists 2019;44(4):379–84.
- [7] Maffei N, et al. SIS epidemiological model for adaptive RT: Forecasting the parotid glands shrinkage during tomotherapy treatment. Medical physics 2016;43(7):e4294.
- [8] X. Wang, J. Lu, X. Xiong, G. Zhu, H. Ying, S. He, W. Hu, and C. Hu. Anatomic and dosimetric changes during the treatment course of intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma. Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists 2010;35(2):151–7.
- [9] Gros SAA, Santhanam AP, Block AM, Emami B, Lee BH, Joyce C. Retrospective clinical evaluation of a decision-support software for adaptive radiotherapy of head and neck cancer patients. Frontiers in Oncology 2022;12:e777793.
- [10] Duma MN, Kampfer S, Schuster T, Winkler C, Geinitz H. Adaptive radiotherapy for soft tissue changes during helical tomotherapy for head and neck cancer. Strahlentherapie und Onkologie 2012;188(3):243–7.
- [11] Fung WW, Wu VW, Teo PM. Dosimetric evaluation of a three-phase adaptive radiotherapy for nasopharyngeal carcinoma using helical tomotherapy. Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists 2012;37(1):92–7.
- [12] Kuo YC, Wu TH, Chung TS, Huang KW, Chao KS, Su WC, Chiou JF. Effect of regression of enlarged neck lymph nodes on radiation doses received by parotid glands during intensity-modulated radiotherapy for head and neck cancer. American Journal of Clinical Oncology 2006;29(6):600–5.
- [13] Hansen EK, Bucci MK, Quivey JM, Weinberg V, Xia P. Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics 2006;64(2):355–62.

- [14] Capelle L, Mackenzie M, Field C, Parliament M, Ghosh S, Scrimger R. Adaptive radiotherapy using helical tomotherapy for head and neck cancer in definitive and postoperative settings: Initial results. Clinical Oncology (Royal College of Radiologists (Great Britain)) 2012;24(3):208–15.
- [15] Brown E, Porceddu S, Owen R, Harden F. Developing an adaptive radiotherapy technique for virally mediated head and neck cancer. Journal of Medical Imaging and Radiation Sciences 2013;44(3):134–40.
- [16] Castelli J, et al. Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the risk of xerostomia. Radiation Oncology 2015;10(6).
- [17] Brown E, Owen R, Harden F, Mengersen K, Oestreich K, Houghton W, Poulsen M, Harris S, Lin C, Porceddu S. Head and neck adaptive radiotherapy: Predicting the time to replan. Asia-Pacific Journal of Clinical Oncology 2016;12(4):460–7.
- [18] Aly F, Miller AA, Jameson MG, Metcalfe PE. A prospective study of weekly intensity modulated radiation therapy plan adaptation for head and neck cancer: Improved target coverage and organ at risk sparing. Australasian Physical and Engineering Sciences in Medicine 2019;42(1):43–51.
- [19] Figen M, Öksüz DÇ, Duman E, Prestwich R, Dyker K, Cardale K, Ramasamy S, Murray P, Şen M. Radiotherapy for head and neck cancer: Evaluation of triggered adaptive replanning in routine practice. Frontiers in Oncology 2020;59(4):960-70.
- [20] Bobić M, Lalonde A, Sharp GC, Grassberger C, Verburg JM, Winey BA, Lomax AJ, Paganetti H. Comparison of weekly and daily online adaptation for head and neck intensity-modulated proton therapy. Physics in Medicine and Biology 2021;66(5):10.1088/1361–6560/abe050.
- [21] Gupta A, Dunlop A, Mitchell A, McQuaid D, Nill S, Barnes H, Newbold K, Nutting C, Bhide S, Oelfke U, Harrington KJ, Wong KH. Online adaptive radiotherapy for head and neck cancers on the MR linear accelerator: Introducing a novel modified adapt-to-shape approach. Clinical and Translational Radiation Oncology 2021; 32:48–51.
- [22] Beetz I. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: The role of dosimetric and clinical factors. Radiotherapy and Oncology 2012;105(1):101–6.
- [23] Wopken K. Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo- radiotherapy in head and neck cancer. Radiotherapy and Oncology 2014;113(1):95–101.
- [24] Dijkema T, Raaijmakers CP, Ten Haken RK, Roesink JM, Braam PM, Houweling AC, Moerland MA, Eisbruch A, Terhaard CH. Parotid gland function after radiotherapy: The combined Michigan and Utrecht experience. International Journal of Radiation Oncology, Biology, Physics 2010;78(2):449–53.
- [25] Lyman JT. Complication probability as assessed from dose-volume histograms. Radiation Research. Supplement 1985;8:S13–9.
- [26] Kutcher GJ, Burman C. Calculation of complication probability factors for non- uniform normal tissue irradiation: The effective volume method. International Journal of Radiation Oncology, Biology, Physics 1989;16(6):1623–30.
- [27] Christianen MEMC. Predictive modelling for swallowing dysfunction after primary (chemo) radiation: Results of a prospective observational study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 2012;105(1):107–14.